Cancer in New Mexico 2025



Please contact us! Phone: 505-272-5541 E-Mail: nmtr-info@salud.unm.edu URL: hsc.unm.edu/new-mexico-tumor-registry/

TABLE OF CONTENTS

| Introduction1 |
|--|
| New Cases of Cancer |
| Estimated Number of New Cancer Cases |
| Description and Methods2 |
| Common Cancer Types for Males and Females3 |
| All Cancers Combined (Map of New Mexico)4 |
| Common Cancer Types by County5 |
| Cancer Incidence Rates |
| Description and Methods6 |
| All Cancers Combined7 |
| Common Cancer Types for Males8 |
| Common Cancer Types for Females9 |
| Cancer Related-Deaths |
| Cancer Mortality Rates |
| Description and Methods10 |
| All Cancers Combined11 |
| Common Cancer Types for Males12 |
| Common Cancer Types for Females13 |

Cancer is a leading cause of illness and death in New Mexico. In 2025, an estimated 10,250 new cases of malignant cancer will be diagnosed among New Mexico residents. This report provides information about the burden of cancer in New Mexico for policy makers, public health professionals, health care providers, researchers and others who need timely and accurate information to support a broad spectrum of cancer control activities.

THE NEW MEXICO TUMOR REGISTRY

Cancer is a reportable disease in New Mexico. The New Mexico Department of Health has identified the New Mexico Tumor Registry as its designee for conducting routine public health surveillance for cancer in the state. The New Mexico Tumor Registry is a population-based cancer registry that has served New Mexico since 1966. The Registry collaborates with health care providers and other professionals throughout the state to identify incident cancer cases through routine and systematic review of existing records such as pathology reports, medical records, radiation therapy records, hospital discharge lists, and vital records. For each new cancer case, the Registry documents selected information about each patient (e.g., age at diagnosis, sex, race/ethnicity, and place of residence), tumor characteristics (e.g., primary anatomical site, histological type, and stage of disease at diagnosis), and first course of cancer-directed therapy (e.g., surgery, chemotherapy, radiation therapy, and hormone therapy).

The New Mexico Tumor Registry is a founding member of the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program – a consortium of cancer registries that provide high quality cancer surveillance data for the United States. Cancer surveillance in New Mexico is conducted in accordance with prevailing standards established by the National Cancer Institute, the North American Association of Central Cancer Registries, and the American College of Surgeons.

CONTENTS

The first section of this report presents estimates of the number of new cancer cases that are expected to occur among New Mexico residents during calendar year 2025. Incidence and mortality rates are useful measures for comparing the occurrence of cancer among racial/ethnic groups while accounting for differences in the size and age-structure of each population. Therefore, the second section focuses on average annual, age-adjusted incidence and mortality rates by type of cancer, based on the most recent five-year period for which actual cancer case counts and deaths are currently available.

DATA SOURCES

Information presented in this report was compiled with records from the New Mexico Tumor Registry, the SEER Program, and National Center for Health Statistics. Denominators for incidence and mortality rate calculations were derived from U.S. Census Bureau figures.

Information regarding deaths due to cancer among New Mexico residents was obtained from the National Center for Health Statistics at the Centers for Disease Control and Prevention. Death certificates issued by individual states, including New Mexico, are routinely submitted to the National Center for Health Statistics for the purpose of monitoring trends in mortality rates for the United States.

Estimated Number of New Cases – Description and Methods

Approximately 10,250 new cancer cases are expected to occur among New Mexico residents during calendar year 2025. These estimates were based on recent years of complete data from the New Mexico Tumor Registry. Specifically, simple linear regression techniques were applied to the annual case counts for calendar years 2018-2022 to estimate the number of cases that would be expected to be observed among New Mexico residents during calendar year 2025.

Estimated case counts for several common types of cancer – statewide – are shown in the graph on page 3. Estimated case counts for all malignant cancers (all cancers combined) are shown by county in the map on page 4. Estimated case counts for several common types of cancer by county are shown in the table on page 5.

Estimated Number of New Cancer Cases – 2025 New Mexico Residents Common Cancer Types

| | Males | | | | | | Femal | es | | | |
|----------------------------------|---------|--------|--------|----------|--------|-------|---------|------------|------|-------|---------|
| 25 | 500 20 | 000 1 | 500 10 | 000 ! | 500 | 0 5 | 500 | 1000 | 1500 | 200 | 0 2500 |
| Breast | | | | 26 | (0.5%) | | - | | | 1,611 | (31.5%) |
| Prostate | 1,465 (| 28.5%) | | | | | | | | | |
| Lung and Bronchus | | | 3 | 74 (7.39 | %) | | 431 | (8.4%) | | | |
| Colon and Rectum | | | 464 | 4 (9.0% |) | | 412 (| 8.1%) | | | |
| Melanoma of the Skin | | | 39 | 90 (7.69 | %) | 22 | 29 (4.5 | 5%) | | | |
| Non-Hodgkin Lymphoma | | | | 185 (3 | 8.6%) | 15 | 2 (3.09 | %) | | | |
| Urinary Bladder | | | 3 | 313 (6.1 | .%) | 91 (| 1.8%) | | | | |
| Kidney and Renal Pelvis | | | | 267 (5. | 2%) | 18 | 6 (3.6 | %) | | | |
| Thyroid | | | | 51 | (1.0%) | 15 | 7 (3.19 | %) | | | |
| Corpus and Uterus, NOS | | | | | | | 363 (7 | 7.1%) | | | |
| Leukemia | | | | 195 (3 | .8%) | 132 | 2 (2.6% | 6) | | | |
| Pancreas | | | | 152 (| 3.0%) | 18 | 2 (3.6 | %) | | | |
| Liver and Intrahepatic Bile Duct | | | | 151 (| 2.9%) | 107 | (2.1% | 5) | | | |
| Oral Cavity and Pharynx | | | | 175 (3 | 3.4%) | 84 (| 1.6%) | | | | |
| Stomach | | | | 104 | (2.0%) | 72 (: | 1.4%) | | | | |
| Ovary | | | | | | 128 | 8 (2.5% | 6) | | | |

Estimated Number of New Cancer Cases – 2025 New Mexico Residents All Cancers Combined



Estimated Number of New Cancer Cases – 2025 New Mexico Residents by County Common Cancer Types

| County | All Cancers Combined | Female Breast | Prostate | Lung and Bronchus | Colon and Rectum | Melanoma of the Skin | Non-Hodgkin Lymphoma | Corpus Uterus | Urinary Bladder | Thyroid |
|---------------|-------------------------|------------------|----------|----------------------|---------------------|-------------------------|-------------------------|------------------|--------------------|---------|
| NM, Statewide | 10,250 | 1,611 | 1,465 | 805 | 876 | 619 | 338 | 363 | 404 | 207 |
| Bernalillo | 3,395 | 623 | 528 | 250 | 253 | 200 | 120 | 111 | 107 | 58 |
| Catron | 32 | 8 | 13 | 2 | 1 | <1 | 1 | <1 | 3 | <1 |
| Chaves | 274 | 40 | 26 | 30 | 16 | 27 | 9 | 9 | 13 | 5 |
| Cibola | 95 | <1 | 10 | 13 | 10 | 1 | <1 | 7 | 3 | 6 |
| Colfax | 75 | 14 | 5 | 9 | 10 | 6 | 5 | <1 | 5 | 4 |
| Curry | 190 | 8 | 25 | 13 | 16 | 23 | 4 | 8 | 9 | 3 |
| De Baca | 1 | <1 | <1 | <1 | <1 | <1 | <1 | <1 | <1 | <1 |
| Doña Ana | 911 | 111 | 75 | 81 | 71 | 52 | 34 | 47 | 38 | 42 |
| Eddy | 264 | 28 | 6 | 31 | 45 | 18 | 8 | 8 | 3 | 9 |
| Grant | 187 | 39 | 23 | 14 | 17 | 10 | <1 | 4 | 11 | 3 |
| Guadalupe | 8 | 3 | 4 | <1 | <1 | 1 | <1 | <1 | <1 | <1 |
| Harding | <1 | <1 | <1 | 1 | <1 | 1 | 1 | <1 | <1 | <1 |
| Hidalgo | 21 | 7 | 1 | <1 | 3 | 2 | 3 | 4 | 2 | <1 |
| Lea | 189 | 27 | 25 | 12 | 10 | 31 | 2 | <1 | 5 | <1 |
| Lincoln | 166 | 28 | 25 | 10 | 11 | 3 | 15 | 2 | 6 | 2 |
| Los Alamos | 62 | 6 | 2 | 3 | 6 | 16 | 3 | 1 | 2 | 2 |
| Luna | 117 | 4 | 7 | 14 | 9 | 1 | 10 | 4 | 4 | 4 |
| McKinley | 228 | 25 | 29 | 11 | 33 | 4 | 11 | 13 | 6 | <1 |
| Mora | 21 | <1 | 8 | 5 | 1 | <1 | <1 | <1 | 1 | <1 |
| Otero | 312 | 49 | 31 | 27 | 21 | 16 | 9 | 12 | 19 | 7 |
| Quay | 52 | 8 | 6 | 6 | 9 | 2 | <1 | 3 | 2 | <1 |
| Rio Arriba | 187 | 24 | 29 | 11 | 21 | 5 | 5 | 10 | 8 | 7 |
| Roosevelt | 83 | 17 | 7 | 9 | 10 | 7 | 7 | <1 | 3 | 1 |
| Sandoval | 909 | 171 | 151 | 69 | 66 | 62 | 26 | 19 | 37 | 30 |
| San Juan | 476 | 64 | 83 | 39 | 63 | 23 | 18 | 13 | 31 | 1 |
| San Miguel | 128 | 11 | 29 | 11 | 14 | 4 | 7 | 4 | 4 | 2 |
| Santa Fe | 1,028 | 171 | 199 | 78 | 72 | 68 | 23 | 55 | 31 | 25 |
| Sierra | 95 | 17 | 7 | 5 | 9 | 7 | <1 | 2 | 10 | 5 |
| Socorro | 80 | 12 | 19 | <1 | 10 | 1 | 3 | 5 | 5 | 2 |
| Taos | 185 | 33 | 29 | 11 | 20 | 11 | 13 | <1 | 6 | 5 |
| Torrance | 81 | 14 | 13 | 1 | 9 | 4 | <1 | 5 | 3 | <1 |
| Union | 10 | 1 | 2 | 4 | <1 | <1 | <1 | <1 | 2 | 2 |
| Valencia | 407 | 56 | 58 | 35 | 47 | 18 | 14 | 23 | 27 | <1 |

Cancer Incidence Rates – Description and Methods

The *incidence rate* is a useful tool for comparing and contrasting the occurrence of cancer among racial/ethnic groups and geographic areas. In the present context, incidence rates measure the "speed" or "velocity" at which members of the target population – New Mexico residents – are diagnosed with cancer during the specified time period.

Cancer can occur at any age, but a majority of cancer cases are diagnosed among older adults. For this reason, comparing cancer rates between two or more populations can be misleading if the underlying age distributions vary among the comparison populations. All incidence rates presented in this report were "age-adjusted" by a common statistical procedure to account for such differences. Specifically, average annual age-adjusted incidence rates were calculated by the direct method and were standardized to the age-distribution of the projected U.S. population for calendar year 2025. Incidence rates were calculated with the National Cancer Institute's SEER*Stat software system.

Statewide cancer incidence rates for all cancers combined by race/ethnic group and sex are shown in the graph on page 7. Incidence rates for several common types of cancer are shown by race/ethnic group in the tables on page 8 (males) and 9 (females).

All Cancers Combined Average Annual Age-Adjusted Incidence Rates New Mexico Residents, 2018-2022



* Data are from 21 SEER Program Registries

Average Annual Age-Adjusted Incidence Rates^{*} Common Cancer Types – Females New Mexico Residents, 2018-2022

| | | United States ^{**} | | | | |
|----------------------------------|--------------------|---------------------------------|--------------|-------------|---------------------------|-----------------------|
| Primary Cancer Type | American Indian | Asian or Pacific Islander | Black | Hispanic | Non- Hispanic White | All Races Combined |
| All Cancers Combined | 263.6 (6.7) | 255.8 (13.6) | 250.5 (13.8) | 366.7 (4.0) | 367.2 (3.7) | 421.3 (0.3) |
| Breast | 59.5 (3.2) | 86.0 (7.7) | 88.6 (8.3) | 116.2 (2.2) | 121.9 (2.1) | 130.8 (0.2) |
| Lung and Bronchus | 10.9 (1.4) | 21.6 (4.0) | 33.1 (5.0) | 26.9 (1.1) | 34.1 (0.9) | 43.9 (0.1) |
| Colon and Rectum | 28.3 (2.2) | 19.1 (3.7) | 26.3 (4.4) | 31.2 (1.2) | 26.0 (1.0) | 32.6 (0.1) |
| Corpus and Uterus | 28.6 (2.2) | 16.6 (3.3) | 21.3 (3.9) | 27.4 (1.1) | 20.9 (0.8) | 28.3 (0.1) |
| Thyroid | 11.3 (1.4) | 21.7 (4.0) | 11.6 (3.1) | 24.9 (1.1) | 16.5 (1.0) | 19.7 (0.1) |
| Melanoma of the Skin | 3.3 (0.8) | 1.1 (0.8) | - | 4.7 (0.4) | 22.9 (1.0) | 17.5 (0.1) |
| Kidney and Renal Pelvis | 17.5 (1.7) | 6.4 (2.0) | 5.4 (2.1) | 15.1 (0.8) | 8.4 (0.6) | 12.0 (0.1) |
| Non-Hodgkin Lymphoma | 10.1 (1.3) | 6.6 (2.3) | 9.4 (2.5) | 12.0 (0.7) | 11.7 (0.6) | 15.7 (0.1) |
| Pancreas | 7.7 (1.2) | 6.1 (2.1) | 5.6 (2.1) | 11.5 (0.7) | 11.1 (0.6) | 12.3 (0.1) |
| Ovary | 10.2 (1.3) | 8.2 (2.4) | 3.0 (1.6) | 9.5 (0.6) | 8.7 (0.6) | 10.3 (0.0) |
| Leukemia | 5.5 (0.9) | 2.8 (1.5) | 5.9 (2.1) | 7.7 (0.6) | 10.1 (0.6) | 11.3 (0.1) |
| Cervix Uteri | 6.1 (1.0) | 7.2 (2.4) | 4.3 (1.8) | 9.7 (0.7) | 7.2 (0.6) | 7.7 (0.0) |
| Urinary Bladder | 1.9 (0.6) | 5.7 (2.1) | 2.9 (1.5) | 5.2 (0.5) | 6.9 (0.4) | 7.7 (0.0) |
| Liver and Intrahepatic Bile Duct | 9.9 (1.3) | 5.4 (2.1) | 2.6 (1.4) | 8.2 (0.6) | 3.5 (0.3) | 5.5 (0.0) |
| Stomach | 9.8 (1.3) | 3.2 (1.5) | 1.5 (1.1) | 7.7 (0.6) | 3.2 (0.3) | 5.7 (0.0) |
| Oral Cavity and Pharynx | 2.3 (0.6) | 5.2 (2.0) | 5.9 (2.2) | 4.1 (0.4) | 6.2 (0.5) | 6.6 (0.0) |
| Myeloma | 5.2 (0.9) | 3.0 (1.6) | 4.5 (1.9) | 4.8 (0.4) | 4.0 (0.3) | 6.1 (0.0) |
| Brain and Other Nervous System | 3.2 (0.7) | 2.6 (1.5) | 1.2 (0.9) | 4.8 (0.4) | 4.4 (0.5) | 5.2 (0.0) |
| Gallbladder and Other Biliary | 5.7 (1.0) | 1.8 (1.1) | 0.6 (0.6) | 3.1 (0.4) | 2.2 (0.3) | 3.0 (0.0) |
| Other Female Genital Organs | 4.5 (0.9) | 2.3 (1.4) | 0.6 (0.6) | 2.6 (0.3) | 2.2 (0.3) | 2.2 (0.0) |

* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population; Standard errors are presented in parentheses

** Data are from 21 SEER Program Registries

Average Annual Age-Adjusted Incidence Rates^{*} Common Cancer Types – Males New Mexico Residents, 2018-2022

| | | United States ^{**} | | | | |
|----------------------------------|--------------------|---------------------------------|--------------|-------------|---------------------------|-----------------------|
| Primary Cancer Type | American Indian | Asian or Pacific Islander | Black | Hispanic | Non- Hispanic White | All Races Combined |
| All Cancers Combined | 274.9 (8.0) | 227.4 (15.0) | 327.2 (15.3) | 362.5 (4.2) | 411.1 (3.7) | 483.5 (0.4) |
| Prostate | 50.6 (3.4) | 45.0 (6.7) | 112.1 (8.7) | 80.2 (1.9) | 94.0 (1.6) | 120.2 (0.2) |
| Colon and Rectum | 42.5 (3.1) | 17.3 (4.2) | 28.8 (4.3) | 41.2 (1.4) | 35.4 (1.2) | 42.3 (0.1) |
| Lung and Bronchus | 12.1 (1.8) | 32.3 (5.8) | 26.3 (4.5) | 32.8 (1.3) | 38.0 (1.0) | 53.1 (0.1) |
| Kidney and Renal Pelvis | 36.3 (2.8) | 9.7 (3.1) | 23.5 (4.1) | 26.7 (1.1) | 16.8 (0.8) | 23.8 (0.1) |
| Melanoma of the Skin | 6.1 (1.4) | - | 0.7 (0.7) | 5.1 (0.5) | 37.7 (1.2) | 27.8 (0.1) |
| Urinary Bladder | 4.9 (1.1) | 8.3 (2.8) | 16.1 (3.4) | 15.7 (0.9) | 28.0 (0.9) | 31.2 (0.1) |
| Non-Hodgkin Lymphoma | 15.0 (2.0) | 19.9 (4.4) | 14.0 (3.7) | 15.3 (0.9) | 17.4 (0.8) | 22.4 (0.1) |
| Leukemia | 7.2 (1.3) | 5.7 (2.4) | 13.7 (3.3) | 13.7 (0.8) | 18.3 (0.9) | 18.2 (0.1) |
| Oral Cavity and Pharynx | 6.7 (1.2) | 14.5 (3.4) | 5.2 (1.7) | 11.3 (0.7) | 17.8 (0.8) | 17.4 (0.1) |
| Liver and Intrahepatic Bile Duct | 14.5 (1.7) | 10.6 (3.0) | 16.1 (3.2) | 22.9 (1.0) | 8.6 (0.5) | 13.9 (0.1) |
| Pancreas | 9.3 (1.5) | 8.9 (3.1) | 9.6 (2.6) | 15.0 (0.8) | 12.5 (0.6) | 15.5 (0.1) |
| Thyroid | 4.1 (0.9) | 6.6 (2.5) | 3.2 (1.3) | 7.3 (0.6) | 8.6 (0.7) | 7.3 (0.0) |
| Stomach | 14.5 (1.8) | 11.1 (3.3) | 6.4 (2.0) | 9.2 (0.7) | 5.3 (0.4) | 9.2 (0.0) |
| Testis | 6.4 (1.0) | 2.6 (1.5) | - | 7.4 (0.6) | 7.3 (0.7) | 6.0 (0.0) |
| Myeloma | 7.0 (1.2) | 3.2 (1.6) | 10.7 (2.9) | 6.8 (0.6) | 6.2 (0.4) | 8.8 (0.0) |
| Esophagus | 4.7 (1.1) | 3.1 (1.6) | 1.9 (1.1) | 5.4 (0.5) | 8.0 (0.5) | 7.1 (0.0) |
| Brain and Other Nervous System | 3.8 (0.8) | 1.7 (1.2) | 2.5 (1.1) | 5.7 (0.5) | 7.7 (0.6) | 7.2 (0.0) |
| Larynx | 2.0 (0.7) | - | 4.3 (1.7) | 3.9 (0.4) | 3.9 (0.4) | 4.4 (0.0) |
| Soft Tissue including Heart | 2.6 (0.8) | 0.8 (0.8) | 0.5 (0.5) | 3.8 (0.4) | 3.1 (0.4) | 4.1 (0.0) |
| Gallbladder and Other Biliary | 4.9 (1.1) | 2.4 (1.7) | 3.5 (1.6) | 4.1 (0.5) | 2.0 (0.3) | 3.1 (0.0) |

* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population; Standard errors are presented in parentheses

** Data are from 21 SEER Program Registries

Cancer Mortality Rates – Description and Methods

Mortality rates are analogous to the incidence rates that were described in the previous section of this report. In contrast to incidence rates, however, deaths due to a specific cancer serve as the numerator in mortality rates. Thus, mortality rates measure the "speed" or "velocity" at which members of the target population – New Mexico residents – died from cancer during the specified time period.

As with incidence rates, average annual age-adjusted mortality rates were calculated by the direct method and were standardized to the age-distribution of the projected US population for calendar year 2025. The mortality rates were calculated for the time period 2019-2023 since these are the most recent years of data currently available from the National Center for Health Statistics. Mortality rates were also calculated with the National Cancer Institute's SEER*Stat software system.

Statewide cancer mortality rates for all cancers combined by race/ethnic group and sex are shown in the graph on page 11. Mortality rates for several common types of cancer are shown by race/ethnic group in the tables on page 12 (males) and 13 (females).

All Cancers Combined Average Annual Age-Adjusted Mortality Rates New Mexico Residents, 2019-2023



Average Annual Age-Adjusted Mortality Rates^{*} Common Cancer Types – Females New Mexico Residents, 2019-2023

| | | United States ^{**} | | | | |
|----------------------------------|--------------------|---------------------------------|-------------|-------------|---------------------------|-----------------------|
| Primary Cancer Type | American Indian | Asian or Pacific Islander | Black | Hispanic | Non- Hispanic White | All Races Combined |
| All Cancers Combined | 92.8 (4.0) | 67.1 (7.0) | 103.0 (8.9) | 121.2 (2.2) | 115.6 (1.8) | 126.3 (0.1) |
| Breast | 10.5 (1.3) | 13.1 (3.1) | 24.1 (4.4) | 18.9 (0.9) | 20.8 (0.8) | 19.2 (0.0) |
| Lung and Bronchus | 5.5 (1.0) | 10.4 (2.7) | 12.8 (3.1) | 16.1 (0.8) | 21.7 (0.7) | 27.1 (0.0) |
| Colon and Rectum | 10.0 (1.3) | - | 7.5 (2.3) | 11.9 (0.7) | 9.1 (0.5) | 10.8 (0.0) |
| Corpus and Uterus | 4.1 (0.8) | - | 6.2 (2.0) | 5.5 (0.5) | 4.3 (0.3) | 5.3 (0.0) |
| Thyroid | - | - | - | 0.9 (0.2) | 0.4 (0.1) | 0.5 (0.0) |
| Melanoma of the Skin | - | - | - | 0.7 (0.2) | 1.4 (0.2) | 1.3 (0.0) |
| Kidney and Renal Pelvis | 3.6 (0.8) | - | - | 3.3 (0.4) | 1.9 (0.2) | 2.1 (0.0) |
| Non-Hodgkin Lymphoma | 2.5 (0.7) | - | - | 3.5 (0.4) | 3.3 (0.3) | 3.7 (0.0) |
| Pancreas | 5.8 (1.0) | - | 7.2 (2.3) | 10.1 (0.6) | 8.8 (0.5) | 9.9 (0.0) |
| Ovary | 7.0 (1.1) | 6.7 (2.2) | - | 5.6 (0.5) | 5.2 (0.4) | 5.9 (0.0) |
| Leukemia | 2.3 (0.6) | - | - | 3.8 (0.4) | 4.0 (0.4) | 4.4 (0.0) |
| Cervix Uteri | 1.8 (0.6) | - | - | 3.0 (0.4) | 1.6 (0.3) | 2.2 (0.0) |
| Urinary Bladder | - | - | - | 2.1 (0.3) | 2.3 (0.2) | 2.0 (0.0) |
| Liver and Intrahepatic Bile Duct | 8.6 (1.2) | - | - | 7.4 (0.5) | 3.4 (0.3) | 4.3 (0.0) |
| Stomach | 5.3 (0.9) | - | - | 3.9 (0.4) | 1.0 (0.2) | 2.0 (0.0) |
| Oral Cavity and Pharynx | - | - | - | 1.1 (0.2) | 1.3 (0.2) | 1.4 (0.0) |
| Myeloma | - | - | - | 2.4 (0.3) | 1.8 (0.2) | 2.4 (0.0) |
| Brain and Other Nervous System | 2.0 (0.6) | - | - | 3.2 (0.4) | 3.7 (0.3) | 3.6 (0.0) |
| Gallbladder and Other Biliary | 2.5 (0.6) | - | - | 1.7 (0.3) | 1.2 (0.2) | 1.1 (0.0) |
| Other Female Genital Organs | - | - | - | 0.7 (0.2) | 0.6 (0.1) | 0.5 (0.0) |

* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population; Standard errors are presented in parentheses

** Data are from 21 SEER Program Registries

Average Annual Age-Adjusted Mortality Rates^{*} Common Cancer Types – Males New Mexico Residents, 2019-2023

| | | United States ^{**} | | | | |
|----------------------------------|--------------------|---------------------------------|--------------|-------------|---------------------------|-----------------------|
| Primary Cancer Type | American Indian | Asian or Pacific Islander | Black | Hispanic | Non- Hispanic White | All Races Combined |
| All Cancers Combined | 119.2 (5.4) | 78.5 (9.1) | 135.7 (10.6) | 162.5 (2.9) | 152.2 (2.1) | 171.5 (0.1) |
| Prostate | 18.6 (2.4) | 11.4 (3.8) | 38.3 (6.2) | 20.2 (1.1) | 19.2 (0.7) | 19.2 (0.0) |
| Colon and Rectum | 15.1 (1.9) | 8.8 (2.8) | 14.3 (3.3) | 18.0 (0.9) | 12.9 (0.7) | 15.3 (0.0) |
| Lung and Bronchus | 8.8 (1.5) | 20.5 (4.7) | 14.4 (3.4) | 24.5 (1.1) | 26.7 (0.9) | 37.2 (0.1) |
| Kidney and Renal Pelvis | 10.1 (1.6) | - | - | 6.7 (0.6) | 4.2 (0.3) | 5.1 (0.0) |
| Melanoma of the Skin | - | - | - | 1.3 (0.3) | 3.8 (0.4) | 3.0 (0.0) |
| Urinary Bladder | - | - | - | 3.9 (0.5) | 7.6 (0.5) | 7.1 (0.0) |
| Non-Hodgkin Lymphoma | 5.6 (1.2) | - | - | 4.8 (0.5) | 5.2 (0.4) | 6.4 (0.0) |
| Leukemia | 3.6 (0.8) | - | - | 5.8 (0.5) | 7.0 (0.5) | 7.8 (0.0) |
| Oral Cavity and Pharynx | - | - | - | 3.5 (0.4) | 4.3 (0.4) | 4.1 (0.0) |
| Liver and Intrahepatic Bile Duct | 12.4 (1.7) | - | 11.5 (2.8) | 17.6 (0.9) | 7.4 (0.5) | 9.4 (0.0) |
| Pancreas | 6.0 (1.2) | - | 8.8 (2.5) | 13.4 (0.8) | 10.8 (0.6) | 12.9 (0.0) |
| Thyroid | - | - | - | 1.0 (0.2) | 0.5 (0.1) | 0.5 (0.0) |
| Stomach | 10.1 (1.6) | - | - | 5.4 (0.5) | 2.2 (0.2) | 3.5 (0.0) |
| Testis | - | - | - | 0.6 (0.2) | - | 0.3 (0.0) |
| Myeloma | 2.6 (0.8) | - | - | 3.7 (0.4) | 3.2 (0.3) | 3.7 (0.0) |
| Esophagus | 4.3 (1.0) | - | - | 4.8 (0.5) | 7.3 (0.5) | 6.5 (0.0) |
| Brain and Other Nervous System | - | - | - | 4.2 (0.4) | 5.9 (0.5) | 5.3 (0.0) |
| Larynx | - | - | - | 1.3 (0.2) | 1.5 (0.2) | 1.6 (0.0) |
| Soft Tissue including Heart | - | - | - | 1.9 (0.3) | 0.7 (0.2) | 1.5 (0.0) |
| Gallbladder and Other Biliary | - | - | - | 1.6 (0.3) | 0.8 (0.2) | 0.9 (0.0) |

* Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population; Standard errors are presented in parentheses

** Data are from 21 SEER Program Registries